155 related articles for article (PubMed ID: 37778409)
1. Antiviral combination therapies for persistent COVID-19 in immunocompromised patients.
Focosi D; Maggi F; D'Abramo A; Nicastri E; Sullivan DJ
Int J Infect Dis; 2023 Dec; 137():55-59. PubMed ID: 37778409
[TBL] [Abstract][Full Text] [Related]
2. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study.
Calderón-Parra J; Gutiérrez-Villanueva A; Ronda-Roca G; Jimenez MLM; de la Torre H; Ródenas-Baquero M; Paniura-Pinedo M; Lozano-Llano C; Pintos-Pascual I; Fernández-Cruz A; Ramos-Martínez A; Muñez-Rubio E
Int J Antimicrob Agents; 2024 Mar; 63(3):107095. PubMed ID: 38244814
[TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma may be a possible treatment for COVID-19: A systematic review.
Wang Y; Huo P; Dai R; Lv X; Yuan S; Zhang Y; Guo Y; Li R; Yu Q; Zhu K
Int Immunopharmacol; 2021 Feb; 91():107262. PubMed ID: 33338863
[TBL] [Abstract][Full Text] [Related]
5. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern.
Casadevall A; Focosi D
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36919696
[TBL] [Abstract][Full Text] [Related]
7. Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review.
Kinsella PM; Moso MA; Morrissey CO; Dendle C; Guy S; Bond K; Sasadeusz J; Slavin MA
Transpl Infect Dis; 2024 Jun; 26(3):e14301. PubMed ID: 38809102
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
[TBL] [Abstract][Full Text] [Related]
9. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients.
Huygens S; Gharbharan A; Serroukh Y; Snoek B; Franken B; Oude Munnink BB; Van Hagen PM; Bogers S; Geurtsvankessel CH; Rijnders BJA
J Antimicrob Chemother; 2023 Jul; 78(7):1644-1648. PubMed ID: 37248664
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.
Senefeld JW; Franchini M; Mengoli C; Cruciani M; Zani M; Gorman EK; Focosi D; Casadevall A; Joyner MJ
JAMA Netw Open; 2023 Jan; 6(1):e2250647. PubMed ID: 36633846
[TBL] [Abstract][Full Text] [Related]
11. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
Bronstein Y; Adler A; Katash H; Halutz O; Herishanu Y; Levytskyi K
J Med Virol; 2022 Mar; 94(3):1241-1245. PubMed ID: 34755363
[TBL] [Abstract][Full Text] [Related]
12. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
[TBL] [Abstract][Full Text] [Related]
13. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
Cantini F; Goletti D; Petrone L; Najafi Fard S; Niccoli L; Foti R
Drugs; 2020 Dec; 80(18):1929-1946. PubMed ID: 33068263
[TBL] [Abstract][Full Text] [Related]
14. B-cell malignancies and COVID-19: a narrative review.
Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F;
Clin Microbiol Infect; 2023 Mar; 29(3):332-337. PubMed ID: 36336236
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
16. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
[TBL] [Abstract][Full Text] [Related]
17. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
18. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY
Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
20. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
